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Abstract Background: Anti-programmed cell death receptor-1 (PD-1) antibodies represent
an effective treatment option for metastatic melanoma as well as for other cancer entities.
They act via blockade of the PD-1 receptor, an inhibitor of the T-cell effector mechanisms that
limit immune responses against tumours. As reported for ipilimumab, the anti-PD-1 anti-
bodies pembrolizumab and nivolumab can induce immune-related adverse events (irAEs).
These side-effects affect skin, gastrointestinal tract, liver, endocrine system and other organ
systems. Since life-threatening and fatal irAEs have been reported, adequate diagnosis and
management are essential.
Methods and findings: In total, 496 patients with metastatic melanoma from 15 skin cancer
centers were treated with pembrolizumab or nivolumab; 242 side-effects were described in
138 patients. In 116 of the 138 patients, side-effects affected the skin, gastrointestinal tract,
liver, endocrine, and renal system. Rare side-effects included diabetes mellitus, lichen planus,
and pancreas insufficiency due to pancreatitis.
Conclusion: Anti-PD1 antibodies can induce a plethora of irAEs. The knowledge of them will
allow prompt diagnosis and improve the management resulting in decreased morbidity.
ª 2016 Elsevier Ltd. All rights reserved.
1. Introduction
Nivolumab and pembrolizumab have been shown to
enhance pre-existing immune responses including anti-
tumour response by directly blocking programmed cell
death receptor-1 (PD-1) which is a checkpoint of the
effector stage of the immune system [1,2]. While the
response rate of ipilimumab-treated patients is around
10e15% [3,4], response rates of pembrolizumab- and
nivolumab-treated patients are 33% [5] and 32% [6],
respectively.
Grade 3e4 adverse events (AEs) are observed in
22e24% of ipilimumab-treated patients [7,8], in
5e10% of nivolumab- and pembrolizumab-treated
patients [5,6] and in 54e55% of ipilimumab plus
nivolumab-treated patients [8,9]. A permanent
discontinuation of therapy due to side-effects has been
reported in 5% of patients treated with anti-PD-1
antibodies [10]. All checkpoint inhibitors can poten-
tially induce immune-related AEs (irAEs) in any organ
system. In contrast to ipilimumab, treatment with
anti-PD-1 antibodies is continuous with some studies
finishing application after 2 years. Thus, irAEs can
occur late after initiation of therapy but possibly also
after cessation of therapy. To date, cases of rare life-
threatening or even fatal side-effects have been re-
ported after anti-PD-1 antibody therapy like severe
skin reactions [11], diabetes mellitus type 1 [12], and
rhabdomyolysis [13].
Both nivolumab and pembrolizumab are approved
for treatment of metastatic melanoma, nivolumab also
for squamous non-small-cell lung cancer (NSCLC) after
prior chemotherapy. Since they are also effective in
various other tumour entities, they are expected to be
employed widely. Therefore, physicians should be aware
of potential side-effects. To facilitate prompt diagnosis
and adequate management, cutaneous, gastrointestinal,
hepatic, endocrine, and renal side-effects are summar-
ised. Rare and therapeutically challenging side-effects
from 15 cancer centers in Germany and Switzerland are
described in detail.
2. Methods
2.1. Ethics statement
This retrospective study was approved by the local
institutional review board of the Friedrich-Alexander-
University Erlangen-Nuremberg (approval number
17_16Bc). In addition, all clinical protocols were
reviewed and approved by the local institutional review
boards of each participating center and were performed
according to Good Clinical Practice and the Helsinki
Declaration.
2.2. Study centers and treatment settings
Fifteen participating study centers in Germany and
Switzerland screened patient files for pembrolizumab-
and nivolumab-associated irAEs and reported them.
AEs were graded according to the National Cancer
Institute Common Toxicity Criteria (CTC, version 4.0).
If not otherwise stated, pembrolizumab was adminis-
tered intravenously over 30 min at a dose of 2 mg/kg
body weight every 3 weeks and nivolumab over 60 min
at a dose of 3 mg/kg body weight every 2 weeks. Based
upon the authors’ discretion, additional information
was requested for the 15 most compelling and instruc-
tive cases of cutaneous, gastrointestinal, hepatic, endo-
crine, and renal side-effects.
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3. Results
A total of 496 melanoma patients were treated with
nivolumab or pembrolizumab at 15 skin cancer centers;
242 irAEs were reported in 138 patients. In 116 of the
138 patients, side-effects affected skin (43 patients),
endocrine system (30 patients), gastrointestinal tract (21
patients), liver (11 patients), pancreas (9 patients), and
the renal system (2 patients).
3.1. Skin
Skin reactions are the most common side-effects under
treatment with anti-PD-1 or anti-cytotoxic T-lympho-
cyte-associated protein 4 (CTLA-4) antibodies and play
an important role for patients. Under treatment with
ipilimumab, up to 50% of the patients suffer from pru-
ritus and rash with very few serious adverse skin re-
actions (grade 3e5) [4,14,15]. Patients had skin reactions
like rash and pruritus in 28e37% and vitiligo in 9e11%
under nivolumab and pembrolizumab [5,16]. Further-
more, rare cutaneous side-effects like exacerbating pso-
riasis vulgaris [17e20], exfoliative dermatitis [20], and
erythema multiforme [20,21] have been documented.
Therapy with anti-PD-1 antibodies may also increase
radiosensitivity and can thus in combination with
radiotherapy induce acute skin reaction [11] similarly
reported for B-Raf proto-oncogene, serine/threonine
kinase (BRAF) inhibitors [22,23]. Also a case of lichen
planus pemphigoides under treatment with pem-
brolizumab [24] and two cases of an induced bullous
pemphigoid [25,26] were reported.
In our analysis, 43 patients (8.7%) presented with
dermatological side-effects (Table 1). These included
common skin events like pruritus, rash and eczema in 19
patients (3.8%), vitiligo in 13 patients (2.6%), alopecia in 7
patients (1.4%), and lichenoid and cytotoxic skin re-
actions in 4 patients (0.8%). Psoriasis vulgaris and lichen
planus mucosae were reported in two patient each.
Sweet’s syndrome, lichen planus, and lichen sclerosus et
atrophicus were documented in one patient each. Only
three cutaneous AEsdlichenoid skin reaction, lichen
ruber mucosae, and Sweet’s syndromedwere graded as
severe, i.e. grade 3. All other events were documented as
grade 1e2 and could be managed with topical cortico-
steroids, systemic antihistaminic therapy, or did not
require treatment.Only one patient with pruritus received
systemic corticosteroid therapy. All grade 3 AEs led to
pause of treatment with anti-PD-1 and resolved or
improved even after continuation of anti-PD-1. The pa-
tient with lichenoid skin reaction received systemic
prednisolone (1 mg/kg body weight orally [p.o.]).
3.1.1. Patient 1dVitiligo of the skin
A 55-year-old male patient with metastatic melanoma
stage IV was treated with pembrolizumab. After 44
weeks of treatment, the patient developed a distinctive
vitiligo with accentuation of his face and chest (Fig. 1A).
3.1.2. Patient 2dVitiligo of the hair
After systemic therapy with vemurafenib and ipilimu-
mab, a 53-year-old woman with stage IV metastatic
melanoma received pembrolizumab (10 mg/kg body
weight intravenous [i.v.]) every 3 weeks. Eighteen weeks
after the first cycle with pembrolizumab, the patient
developed depigmentation of her eyelashes, eyebrows
(Fig. 1B), and her axillary and pubic hair which still
persists.
3.1.3. Patient 3dLichen planus mucosae
An 87-year-old male patient, pretreated with radiation
therapy, carboplatin/paclitaxel and ipilimumab, was
started on treatment with pembrolizumab. In addition
to pneumonitis, vitiligo, and autoimmune hepatitis, the
patient developed white pruritic and reticular plaques in
his buccal cavity and on his tongue (Fig. 2A) approxi-
mately 1 year after initiation of anti-PD-1 treatment.
Furthermore, he had a painful erosion on his glans penis
(Fig. 2A). Histopathological analysis confirmed the
diagnosis of lichen ruber planus mucosae. Direct and
indirect immunofluorescence, antinuclear antibody
(ANA) titer, and anti-desmoglein-3 and anti-
desmoglein-1 antibodies were negative. Topical ther-
apy with triamcinolone acetonide (adhesive ointment)
for the buccal mucosa and with methylprednisolone for
the balanitis was initiated. In addition, systemic anal-
gesic therapy and local antiseptic therapy were admin-
istered. Four weeks later, almost all buccal and genital
skin changes had resolved. Pembrolizumab was paused
for 3 weeks and the lichen planus mucosae did not
recidivate upon continuation of anti-PD1 therapy.
3.1.4. Patient 4dLichen planus
A 46-year-old patient started treatment with pem-
brolizumab for metastatic melanoma. After eight cycles,
he developed painful and itchy hyperkeratotic papules
and nodules at his hands, feet, forearms, and trunk
(Fig. 2B). Histopathological analysis revealed lichen
planus with hypergranulosis, orthohyperkeratosis, and
dense lichenoid infiltrate in the upper corium and some
apoptotic keratinocytes (civatte bodies; Fig. 2B). Local
treatment with corticosteroids and urea- and salicylic
acid-containing ointments as well as systemic therapy
with levocetirizine 5 mg per day were started. After a
few weeks, the skin lesions improved markedly.
Computed tomography (CT) scans revealed regression
of metastases. Treatment with pembrolizumab is
currently ongoing. Local treatment with corticosteroids
and urea- and salicylic acid-containing ointments as well
as systemic therapy with levocetirizine 5 mg per day is
continued.
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Table 1
Cutaneous side-effects of anti-PD1 therapy.
Type of side-effect Grade
CTCAE
Anti-PD-1
antibody
Occurrence
in week(s)
after initiation
of anti-PD-1
Treatment of side-effect Outcome of
side-effect
Clinical tumour
response to
anti-PD-1
Gender
(female/
male)
Age Pre-treatments
Vitiligo 1 n 11 No treatment Not resolved PR f 53 No prior treatment
Vitiligo
(hypopigmentation
around naevi)
1 n 35 No treatment Not resolved PR m 66 No prior treatment
Vitiligo 1 p 54 No treatment Not resolved SD f 61 Dacarbazine; ipilimumab;
carboplatin/paclitaxel;
fotemustine
Vitiligo 1 p 39 No treatment Not resolved PR m 46 Binimetinib; dacarbazine;
anti-endosialin-antibody;
ipilimumab
Vitiligo 2 p 20 No treatment Not resolved PR f 71 Polychemotherapy with
hydroxyurea; dacarbazine;
carmustine
Vitiligo of hair 1 p 18 No treatment Not resolved PR f 53 Vemurafenib; ipilimumab
Lichen planus mucosae 2 n 43 Topical corticosteroids; topical pimecrolimus;
stomatitis mouthwash solution
Improved PD f 65 No prior treatment
Alopecia 1 p 27 No treatment Improved SD m 52 Interferon-alpha;
Mage-A3 vaccine;
paclitaxel; ipilimumab
(including 2 reinductions);
polychemotherapy;
intranodal vaccine; radiotherapy
Pruritus 1 p 4 No treatment Improved PD m 68 Temozolomid; cisplatin;
sorafenib; irinotecan;
ipilimumab
Pruritus 1 p 24 Topical triclosan; topical corticosteroids;
topical polidocanol
Not resolved PR f 65 Dacarbazine; ipilimumab
Pruritus/eczema 1 n 24 Topical methylprednisolone Not resolved PR f 34 No prior treatment
Pruritus/xerosis cutis 1 n 2 No treatment Not resolved PD m 70 Electrochemotherapy;
ipilimumab
Pruritus/eczema 2 p 4 Topical corticosteroids; systemic
corticosteroids 0.5 mg/kg/d p.o.; pause of
pembrolizumab
Improved PR m 54 Dacarbazine; ipilimumab;
radiotherapy; carboplatin/
paclitaxel
Pruritus 1 p 1 Topical methylprednisolone Resolved SD m 79 Radiotherapy;
ipilimumab
Pruritus 2 p 4 Fexofenadin 180 mg/d; topical corticosteroids Resolved SD m 66 Interferon-alpha;
radiotherapy
Pruritus 2 p 9 Clemastine fumarate p.o., hydroxyzine
dihydrochloride 25 mg/d p.o.
Not resolved PD m 53 Interferon-alpha;
ipilimumab; dacarbazine;
carboplatin/paclitaxel;
radiotherapy
(continued on next page)
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Table 1 (continued )
Type of side-effect Grade
CTCAE
Anti-PD-1
antibody
Occurrence
in week(s)
after initiation
of anti-PD-1
Treatment of side-effect Outcome of
side-effect
Clinical tumour
response to
anti-PD-1
Gender
(female/
male)
Age Pre-treatments
Erysipelas-like skin
inflammation around
responding cutaneous
metastases
2 n 6 No treatment Ongoing SD m 60 Interferon-alpha;
interferon pegylated;
ipilimumab
Eczema 1 n 4 Topical corticosteroids Resolved PD m 78 Interferon-alpha
Pruritus 2 p 1 Topical corticosteroids; topical polidocanol Resolved PD m 59 Radiotherapy;
ipilimumab
Rash 2 p 1 Topical corticosteroids; topical polidocanol Resolved PD m 59 Radiotherapy;
ipilimumab
Hair growth (body) 1 p 26 No treatment Not resolved PR m 55 Interferon-alpha;
radiotherapy; dacarbazine;
ipilimumab; vemurafenib
Hyperkeratosis (body) 1 p 26 No treatment Not resolved PR m 55 Interferon-alpha;
radiotherapy; dacarbazine;
ipilimumab; vemurafenib
Vitiligo 2 p 44 No treatment Not resolved PR m 55 Interferon-alpha;
radiotherapy; dacarbazine;
ipilimumab; vemurafenib
Pruritus/eczema 2 p 1 Topical hydrocortisone; topical mometasone
furoate; topical urea
Improved SD f 81 Dacarbazine; SIRT;
ipilimumab; radiotherapy
Rash face 2 p 1 Topical hydrocortisone; topical mometasone
furoate; topical ketoconazole
Resolved SD f 81 Dacarbazine; SIRT;
ipilimumab; radiotherapy
Vitiligo 1 p 1 No treatment Not resolved PR m 69 Radiochemotherapy;
carboplatin/paclitaxel;
ipilimumab
Pruritus 1 p 1 Indifferential topical therapy;
antihistaminic p.o.
Resolved PR m 69 Radiochemotherapy;
carboplatin/paclitaxel;
ipilimumab
Pruritus 1 p 12 No treatment Not resolved PR m 64 Radiotherapy;
dacarbazine; carboplatin/
paclitaxel; ipilimumab
Pruritus 1 p 27 Indifferential topical therapy Improved CR m 54 Interferon-alpha; DC vaccine;
ipilimumab
Hyperkeratosis (fingers) 2 p 3 No treatment Not resolved PD m 49 Interferon-alpha;
radiotherapy; ipilimumab;
dabrafenib; dabrafenib/
trametinib
Pruritus 2 p 1 Topical corticosteroids; topical polidocanol Resolved SD m 69 Interferon-alpha;
dacarbazine; ipilimumab
Lichenoid skin reaction 3 p 1 Prednisolone 1 mg/kg/d; pause of pembrolizumab Resolved PD m 79 Ipilimumab
Vitiligo 1 p 51 No treatment Not resolved PR m 74 Ipilimumab
Lichenoid skin reaction 1 p 54 No treatment Resolved PR m 74 Ipilimumab
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Vitiligo 1 p 50 No treatment Not resolved PR m 49 MEK inhibitor/
panBRAF-inhibitor;
ipilimumab; cisplatin/
vindesine
Cytotoxic skin reaction 1 p 3 Topical corticosteroids; indifferential topical
therapy
Resolved SD m 83 Ipilimumab
Rash 1 p 7 Topical corticosteroids Resolved PR m 35 Ipilimumab
Rash 1 p 6 Topical corticosteroids Resolved PR m 68 Ipilimumab
Vitiligo 1 p 50 No treatment Not resolved PR m 68 Ipilimumab
Vitiligo 1 p 25 No treatment Not resolved PR m 80 Dacarbazine; ipilimumab
Lichenoid skin reaction 1 p 38 Topical corticosteroids Not resolved PR m 80 Dacarbazine; ipilimumab
Vitiligo 1 p 3 No treatment Not resolved PD f 57 Ipilimumab
Cold hands 1 n 1 No treatment Resolved PR m 76 Ipilimumab (including
reinduction); radiotherapy
Lichen sclerosus et
atrophicus
1 n 68 No treatment Resolved PR m 76 Ipilimumab (including
reinduction); radiotherapy
Alopecia 1 n 75 No treatment Resolved PR f 62 Interferon-alpha
Febrile neutropenia with
rash (sweet’s syndrome)
3 n 10 Pause of nivolumab Resolved CR f 70 No prior treatment
Alopecia 1 n 22 No treatment Not resolved CR f 70 No prior treatment
Penis oedema 1 n 7 No treatment Resolved PR m 71 No prior treatment
Psoriasis vulgaris 1 n 53 Topical calcipotriol and betamethasone Not resolved PR m 71 No prior treatment
Alopecia 1 n 7 No treatment Not resolved SD f 59 Ipilimumab
Atopic dermatitis (worsening) 1 n 2 Topical moisturising ointment Not resolved PD m 45 Interferon-alpha;
ipilimumab; radiotherapy
Alopecia (loss of eyelashes) 1 p 11 No treatment Resolved PR f 29 Interferon-alpha;
dacarbazine; ipilimumab;
paclitaxel
Alopecia (loss of eyelashes) 1 p 35 No treatment Resolved PR f 29 Interferon-alpha;
dacarbazine; ipilimumab;
paclitaxel
Decreased growth of hair
(body)
1 p 19 No treatment Not resolved PR f 29 Interferon-alpha;
dacarbazine; ipilimumab;
paclitaxel
Lichen planus 2 p 21 Topical corticosteroids and urea- and
acetylsalicylic acid-containing
ointments; systemic levocetirizine 5 mg/d
Improved PR m 45 Interferon-alpha;
dacarbazine/darleukin;
ipilimumab; carboplatin/
paclitaxel
Psoriasis vulgaris
(worsening)
2 p 2 Topical therapy Improved SD m 69 Interferon-alpha;
dacarbazine; ipilimumab
Lichen planus mucosae 3 p 49 Topical triamcinolone and methylprednisolone;
topical antiseptic therapy; systemic analgesic
therapy; pause of pembrolizumab
Improved PR m 69 Radiochemotherapy;
carboplatin/paclitaxel;
ipilimumab
Exanthema (maculated) 2 p 1 Prednisolone 60 mg/d p.o. over 3 d;
cetirizine p.o.
Improved n/a f 30 Radiotherapy;
interferon-alpha; DC vaccine
Abbreviations: p, pembrolizumab; n, nivolumab; CTCAE, Common Terminology Criteria for Adverse Events; SD, stable disease, PR, partial response; CR, complete response, PD, progressive disease;
n/a, not applicable; SIRT, selective internal radiation therapy; DC, dendritic cell; p.o., oral.
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3.1.5. Patients 5, 6 and 7dalopecia
Patient 5: A 62-year-old female patient complained
about hair loss starting after 35 infusions of nivolumab
as first-line treatment of metastatic melanoma. Apart
from that, she had tolerated the therapy well. The degree
of hair loss varied but a wig or other therapeutic
intervention was not needed. Under ongoing anti-PD-1
treatment, the AE resolved after 2 months.
Patient 6: A 70-year-old female patient complained
about hair loss starting after eight infusions of nivolu-
mab as first-line treatment of metastatic melanoma. The
patient was terrified from the sudden onset of hair loss
Fig. 1. (A) Vitiligo of the skin: depigmentation of the upper body and head with a bizarre and irregular border under black light in a
melanoma patient after 44 weeks under treatment with pembrolizumab. (B) Vitiligo of the hair: eyebrows and eyelashes of a 53-year-old
female patient before (a) and 18 weeks after treatment with pembrolizumab (b).
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Fig. 2. (A) Lichen planus mucosae: 87-year-old male patient with pruritic, reticular white lines on the tongue (a, b) and an erosion of the
glans penis (c) 49 weeks after initiation of pembrolizumab. (B) Lichen planus: on both palms of a 46-year-old pembrolizumab-treated male
patient circumscribed, disseminated, and reddened papules with a shiny surface (a). Biopsy of the back of the hand with hyperkeratosis,
wedge-shaped acanthosis, subepidermal dense lichenoid infiltrate of small lymphocytes that obscures the dermaleepidermal interface (b).
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and chose to wear a wig. The degree of hair loss varied
over time and was judged not to be severe. After two-
and-a-half months, the AE resolved without interrup-
tion of anti-PD-1 treatment.
Patient 7: A 59-year-old female patient received
three infusions of nivolumab because of progressive
metastatic melanoma after therapy with ipilimumab.
She complained about increasing hair loss. The density
of her hair was reduced in all areas but mainly in a circle
at the parietal region. Signs of hair loss alternate with
hair growth at the parietal region and are ongoing, but
not severe.
3.1.6. Patient 8dPsoriasis vulgaris
After 53 weeks of treatment with nivolumab, a 71-year-
old male patient developed erythema and scales on his
face. He had no history of psoriasis or atopic dermatitis.
Topical treatment with hydrocortisone gel, followed by
metronidazole under the suspected diagnosis of
corticosteroid-induced dermatitis or rosacea was star-
ted. Contact allergy was ruled out by epicutaneous
testing. Histology showed a subacute eczema with
acanthokeratosis, parahyperkeratosis and spongiosis.
The lesions slowly spread and psoriasis was diagnosed
presenting with patches of thick, red, and scaly skin on
the whole body (including elbows, knees, groins and
genital). Under topical therapy including vitamin D
analogues in combination with corticosteroids, the
skin lesions improved and after cessation of nivolumab,
psoriasis slowly resolved.
3.2. Gastrointestinal tract
Gastrointestinal irAEs are common under a treatment
with checkpoint inhibitors. Ipilimumab-induced diar-
rhoea and colitis have been described in 32.8% and
abdominal pain in 15.3% with grade 3e4 AEs in
approximately 5% [3,27]. Patients under treatment with
anti-PD-1 antibodies showed gastrointestinal AEs like
diarrhoea in 6.0e16.0% [10,28,29] with grade 3e4 AEs
in up to 2.2% [9,10,29,30]. Compared to ipilimumab, the
incidence and severity of anti-PD-1 antibody-induced
gastrointestinal AEs are much lower [27]. Nevertheless,
intestinal perforations under anti-PD-1 treatment have
been reported. An elevated calprotectin concentration in
the feces before initiation of anti-CTLA-4 antibody
therapy or a rapid increasing concentration under
treatment seems to correlate with more severe
autoimmune-related colitis [31]. As reported for ipili-
mumab to avoid mucosal biopsies, a non-invasive
method for diagnosing checkpoint inhibitor-induced
colitis in vivo is confocal laser endomicroscopy [32].
In this study, 21 patients (4.2%) were reported with
gastrointestinal AEs (Table 2) including diarrhoea (10
patients), colitis (2 patients), abdominal pain (4 patients),
coprostasis (3 patients), xerostomia (3 patients), and
oesophagitis (1 patient). The majority of gastrointestinal
events were mild and only four grade 3 AEs (diarrhoea)
were reported. In persisting grade 2 and grade 3 AEs,
checkpoint inhibitor treatment was interrupted and
prednisolone (1.0e2.0 mg/kg body weight p.o. or i.v.)
administered. Two of the patients suffering from grade 3
diarrhoea received treatment with infliximab (5 mg/kg
body weight i.v.). All gastrointestinal events resolved or
were ongoing but improving.
3.3. Liver
Hepatitis is another side-effect that can be induced
by checkpoint inhibitors. It may be even fatal [3].
Commonly, hepatitis presents with an asymp-
tomatic increase of aspartate transaminase, alanine
transaminase and total bilirubin. Sometimes fatigue and
fever are associated and radiologic signs of a checkpoint
inhibitor-induced hepatitis include hepatomegaly, peri-
portal lymphadenopathy and periportal oedema [33].
Elevated transaminases are reported in <10% in
ipilimumab-treated patients [3,27,34] and in 3.7e10.0%
anti-PD-1 antibody-treated patients [16,35]. Also
a cytomegalovirus (CMV)-induced hepatitis after treat-
ment with ipilimumab has been reported [36]. However,
20% of patients treated for advanced hepatocellular
carcinoma showed an increase in transaminases due to
treatment with nivolumab [37].
In this study, 11 patients (2.2%) developed hepatitis
under treatment with pembrolizumab or nivolumab
(Table 3). All events were grade 3e4 and were subse-
quently treated with prednisolone or methylprednisolone
2 mg/kg body weight p.o. or i.v. while checkpoint in-
hibitors were interrupted or stopped. Three patients also
required treatment with mycophenolate mofetil (500 mg
or 1.0 g twice a day [BID] p.o.). Two events improved but
were ongoing, all other hepatic AEs resolved.
3.3.1. Patient 9dHepatitis
After progressive disease under subsequent therapy with
vemurafenib and ipilimumab, a 53-year-old female pa-
tient with stage IV metastatic melanoma received pem-
brolizumab (10 mg/kg body weight i.v.) every 3 weeks.
Three weeks after the first infusion, the patient pre-
sented in a reduced general condition with massive in-
crease of liver transaminases and painful red eyes with
photophobia diagnosed as grade 3 iritis. Anti-PD-1
treatment was stopped. Liver biopsy revealed peri-
portal and lobular hepatitis infiltrated with eosinophils
and some other inflammatory cells (Fig. 3A). Since
systemic steroids (prednisolone 2 mg/kg body weight
i.v.) induced only a slight improvement in liver trans-
aminases, mycophenolate mofetil 1 g p.o. BID was
added. Hepatic transaminases responded within
24 h and normalised 1 month from the start of myco-
phenolate without relapse. Iritis was treated with
mydriatic agents and dexamethasone eye drops and
resolved completely after 4 weeks.
L. Hofmann et al. / European Journal of Cancer 60 (2016) 190e209198
Table 2
Gastrointestinal side-effects of anti-PD1 therapy.
Type of side-effect Grade
CTCAE
Anti-PD-1
antibody
Occurrence in
week(s) after
initiation of
anti-PD-1
Treatment of side-effect Outcome of
side-effect
Clinical
tumour
response to
anti-PD-1
Gender
(female/
male)
Age Pre-treatments
Diarrhoea 3 p 24 Prednisolone 2 mg/kg/d i.v.; pause of
pembrolizumab
Resolved PR f 71 Polychemotherapy with hydroxyurea;
dacarbazine; carmustine
Lymphocytic colitis
with diarrhoea
3 p 49 Prednisolone 2 mg/kg/d i.v.; infliximab
5 mg/kg i.v.; pause of pembrolizumab
Resolved SD f 68 Isolated limb perfusion; dacarbazine;
fotemustine; vemurafenib; ipilimumab;
temozolomide; electrochemotherapy
with bleomycin
Diarrhoea 2 p 2 Prednisolone 2 mg/kg/d i.v. Resolved PD f 50 No prior treatment
Diarrhoea 3 p 23 Systemic saccharomyces boulardii;
loperamide p.o.; palliative analgesic
therapy
Resolved PD f 40 Interferon-alpha; vemurafenib;
ipilimumab; radiotherapy
Diarrhoea 1 p 4 No treatment Not resolved PD f 44 Interferon-alpha;
dabrafenib; ipilimumab; vemurafenib;
radiotherapy
Colitis 2 p 5 Stop of pembrolizumab; loperamide;
initial prednisolone 140 mg/d, tapering
Resolved SD m 66 Interferon-alpha; radiotherapy
Xerostomia 1 p 21 Saliva spray Resolved PR m 78 No prior treatment
Pain abdomen 1 p 6 No treatment Resolved PD m 67 Interferon-alpha; dacarbazine; vaccine;
radiotherapy; carboplatin/paclitaxel
Diarrhoea 1 p 1, 4 No treatment Resolved PD m 45 Interferon-alpha; dacarbazine;
carboplatin/paclitaxel; carboplatin;
vaccine; radiotherapy; ipilimumab
(including reinduction)
Pain abdomen 1 p 1, 4 No treatment Resolved PD m 45 Interferon-alpha; dacarbazine;
carboplatin/paclitaxel; carboplatin;
vaccine; radiotherapy; ipilimumab
(including reinduction)
Pain abdomen 1 p 15 Fluid replacement p.o.; warm wet pack Resolved PD m 52 Radiotherapy; carboplatin/paclitaxel;
HFTT; ipilimumab
Coprostasis 2 p 1 Dexamethasone p.o. Resolved PR m 55 Interferon-alpha; radiotherapy;
dacarbazine; ipilimumab; vemurafenib
Pain abdomen 1 p 1, 28 No treatment Resolved PR m 64 Radiotherapy; dacarbazine;
carboplatin/paclitaxel; ipilimumab
Oesophagitis 2 p 24 Pantoprazole p.o. Resolved PR m 64 Radiotherapy; dacarbazine;
carboplatin/paclitaxel; ipilimumab
Diarrhoea 3 p 15 First line: prednisolone 80 mg/d p.o.;
second line: pause of pembrolizumab;
infliximab 5 mg/kg i.v.
Improved PR m 68 Radiotherapy; dacarbazine; dabrafenib;
dabrafenib/trametinib; carboplatin/
paclitaxel; ipilimumab
Diarrhoea 2 n 7 Pause of nivolumab; loperamide p.o. Resolved PD f 68 No prior treatment
Diarrhoea 2 n 8 Loperamide p.o.; probiotic bacteria p.o. Not resolved PD f 36 Radiotherapy; ipilimumab; dacarbazine
Xerostomia 1 n 10 No treatment Not resolved PR m 76 Ipilimumab (including reinduction);
radiotherapy
Coprostasis 1 n 6 Polyethylene glycol p.o. as needed Resolved PR m 71 No prior treatment
(continued on next page)
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3.4. Pancreas
Under treatment with anti-CTLA-4 antibodies and anti-
PD-1 antibodies grade 3e4 CTCAE elevated levels of
serum amylase and lipase were reported in <1e2%
[6,20,21,38]. Most of these events were asymptomatic and
required no immunosuppressive therapy [39]. Interest-
ingly, someauthors donot recommend routine assessment
of pancreatic enzymes [14]. In this analysis, nine patients
developed pancreatitis (1.8%) of grade 2e4 under treat-
ment with nivolumab or pembrolizumab (Table 4). All
patients were treated with systemic corticosteroids
((methyl)prednisolone 1.0e2.0 mg/kg body weight) and
treatment was interrupted in four patients. Two patients
(grade 4 AEs) additionally required treatment with
mycophenolate mofetil. Almost all events resolved with
one patient still suffering from pancreas insufficiency.
3.4.1. Patient 10ePancreatitis with pancreas insufficiency
A 65-year-old male patient suffered from stage IV mela-
noma with hepatic and splenic metastases. After pro-
gressive disease under systemic treatment with a mitogen-
activatedproteinkinase (MEK) inhibitor and ipilimumab,
anti-PD-1 therapy with pembrolizumab was started.
Eleven weeks after initiation, the patient suffered from
lack of appetite and pain of his feet. One week later, the
patient complained about increasing anorexia, nausea
after eating, and an aversion against meat andweight loss.
Laboratory findings showed an increased lipase (760 U/l,
normal 13e60 U/l) and amylase (378 U/I, <110 U/l).
Abdominal CT revealed a reduced lobulation, tissue
swelling, and reduced tissue contrast enhancement of the
pancreatic body and tail consistent with a pancreatitis
(Fig. 3B). Systemic therapy with prednisolone (100 mg/
d i.v.) was initiated, and after 3 d of treatment pancreas
enzymesdecreased (lipase 760 to 62U/l andamylase 378 to
99 U/l). Corticosteroid therapy was changed to oral
treatment (prednisolone 1 mg/kg body weight) and
tapered. The following 5months an increase of pancreatic
enzymes was seen intermittently and led to consecutive
enhanced corticosteroid therapy. The first staging 4
months after start of anti-PD-1 therapy showed a mixed
tumour response with regressive hepatic but progressive
splenic metastases. Eight months after start and nearly 2
months after end of treatment with anti-PD-1, the patient
complained about irregular stools with diarrhoea, decol-
ouration of faeces, and absent weight gain despite good
appetite. Now pancreatic enzymes were decreased (lipase
7 U/I, normal 13e60 U/l and amylase 46 U/l, normal
<110 U/l) and scatoscopy showed a decreased level of
elastase (<15 mg/g feces, normal >200 mg/g feces). A
pancreas insufficiency was diagnosed and enzymes
replaced orally with pancreatic enzyme capsules.
Commonly, asymptomatic increases of pancreatic
enzymes have been described so that routine assessment
was not recommended [14]. However, this case leading
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Table 3
Hepatic side-effects of anti-PD1 therapy.
Type of
side-effect
Grade
CTCAE
Anti-PD-1
antibody
Occurrence in
week(s) after
initiation of
anti-PD-1
Treatment of side-effect Outcome of
side-effect
Clinical
tumour
response to
anti-PD-1
Gender
(female/
male)
Age Pre-treatments
Hepatitis 3 p 3 Prednisolone 2 mg/kg/d i.v.; mycophenolate mofetil 2
1 g/d; stop of pembrolizumab
Resolved PR f 53 Vemurafenib;
ipilimumab
Hepatitis 3 p 1 Stop of pembrolizumab; initial prednisolone 2 mg/kg/d,
then: prednisolone 1 g/d i.v.
Resolved PD f 46 Interferon-alpha; ipilimumab;
electrochemotherapy with bleomycin;
interleukin-2 intralesional
Hepatitis 3 p 4 Pause of pembrolizumab;
prednisolone 1 mg/kg/d p.o.
Resolved PR m 69 Radiochemotherapy; carboplatin/paclitaxel;
ipilimumab
Hepatitis 3 n 4 Prednisolone 1 mg/kg/d Resolved PR m 53 No prior treatment
Hepatitis 3 p 3 Prednisolone 2 mg/kg/d Resolved PD f 48 Ipilimumab
Hepatitis 4 p 3 Stop of pembrolizumab;
prednisolone 100 mg/d i.v. 3 d; prednisolone 500 mg/d i.v. 3 d;
prednisolone 250 mg/d i.v. 7 d; mycophenolate mofetil
500 mg 2/d and prednisolone 50 mg/d p.o. 14 d
Resolved PD f 35 Ipilimumab
Hepatitis 4 n 2 Methylprednisolone 2 mg/kg/d; stop of nivolumab Improved PR m 76 Ipilimumab;
radiotherapy
Hepatitis 3 p 4 Pause of pembrolizumab; prednisolone initial 50 mg/d Resolved PD f 75 Dacarbazine;
ipilimumab;
radiotherapy
Hepatitis 3 p 2 Pause of pembrolizumab; methylprednisolone 1 mg/kg/d i.v.,
then p.o. and tapering to prednisolone 5 mg/d
Resolved PR f 56 Ipilimumab
Hepatitis 3 p 18 Stop of pembrolizumab; methylprednisolone 2 mg/kg/d;
mycophenolate mofetil
500 mg 2/d; prednisolone p.o., tapering
Resolved CR m 72 Interferon-alpha; ipilimumab
Hepatitis 3 p 1 Prednisolone 2 mg/kg/d p.o.;
stop of pembrolizumab
Improved n/a m 55 Interferon-alpha; radiotherapy;
ipilimumab
Abbreviations: p, pembrolizumab; n, nivolumab; CTCAE, Common Terminology Criteria for Adverse Events; PR, partial response; CR, complete response, PD, progressive disease; n/a, not applicable;
p.o., oral; i.v., intravenous.
L
.
H
o
fm
a
n
n
et
a
l.
/
E
u
ro
p
ea
n
J
o
u
rn
a
l
o
f
C
a
n
cer
6
0
(
2
0
1
6
)
1
9
0e
2
0
9
2
0
1
to pancreas insufficiency indicates that assessing these
values is important.
3.5. Endocrine system
IrAEs of the endocrine system are well known from ipili-
mumab. Common endocrinopathies under anti-CTLA-4
include hyperthyroidism, hypothyroidism (1.5%), hypo-
physitis (1.8%), and adrenal insufficiency (1.5%) [3,40].
Under treatment with anti-PD-1 antibodies, incidence of
hypothyroidismof anygrade is approximately 8% [39] and
of hyperthyroidism approximately 1e5% [5,20,21].
Endocrine disorders may be difficult to diagnose since
symptoms of hypophysitis for instance can be unspecific
with fatigue, headache, dizziness, vision changes, sweat-
ing, and constipation. Diagnosis is based on hormone
work-up and magnetic resonance imaging (MRI) scans
which might reveal enlargement of the pituitary
gland [41]. Laboratory work-up includes electrolytes,
thyroidea-stimulating hormone (TSH), free triiodothy-
ronine (fT3), free thyroxine (fT4), cortisol, luteinising
hormone, follicle-stimulating hormone, circulating
cortisol, testosterone, and insulin-like growth factor-1.
Upon diagnosis, prompt treatment with hormones, elec-
trolytes, and/or fluid replacement as required are
indicated.
In our analysis, 30 patients (6.0%) developed endo-
crine disorders (Table 5). Approximately 25% of the
events were grade 3e4. Hypothyroidism was reported in
9 patients (1.8%) and hyperthyroidism including
thyroiditis in 11 patients (2.2%). Four patients (0.8%)
developed hypophysitis and two patients adrenal insuf-
ficiency. Furthermore, Hashimoto’s disease was docu-
mented in two cases. Four patients (0.8%) developed
diabetes mellitus under treatment with nivolumab or
pembrolizumab. In all cases, insulin replacement, in one
case an insulin perfusor, had to be initiated and main-
tained. Initial symptoms included increased thirst,
Fig. 3. (A) Hepatitis: histologic presentation of the liver of a 53-year-old female patient showing a (peri-)portal and lobular hepatitis with
eosinophilic infiltrates (/), in haematoxylin and eosin stain (HE) stain, 200 times (a) and 400 times (b) magnified, 3 weeks after the first
pembrolizumab treatment. (B) Pancreatitis with pancreas insufficiency: transversal contrast-enhanced computed tomography scan readily
reveals reduced lobulation, tissue swelling, and reduced tissue contrast enhancement of the pancreatic body and tail consistent with
pancreatitis (white solid arrow) compared to normal pancreatic tissue appearance in the pancreatic body (open arrow). Please note
multifocal hypodense liver metastases of this 65-year-old male patient 11 weeks after initiation of anti-PD-1 treatment with
pembrolizumab.
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vomiting, and ketoacidosis with increased glucose levels
similar to the case of a fulminant diabetes type 1 re-
ported in the literature [12].
3.5.1. Patient 11dHypophysitis
A 52-year-old male patient, treated with ipilimumab
(1 mg/kg body weight i.v.) combined with pem-
brolizumab (2 mg/kg body weight i.v.) as first-line
treatment complained about general weakness, fatigue,
lack of appetite, pressure in his ears, and shivering 17
weeks after initiation of treatment. A few days later, he
also suffered from less saliva. Endocrine blood tests
showed decreased fasting-free cortisol (0 ng/ml, normal
67e226 ng/ml) and adrenocorticotropic
hormone (<5.0 pg/ml, normal 5e50 pg/ml), decreased
testosterone (3.28 ng/ml, normal 3.5e9 ng/ml), increased
interstitial cell-stimulating hormone (8.88 U/l, normal
0.7e6 U/l), increased TSH (6.78 mE/ml, normal
0.4e4.0 mE/ml), increased thyroglobulin (13.10 ng/ml,
normal <1.0 ng/ml), and increased
prolactin (281.1 mlU/l, normal 55.93e278.18 mlU/l). A
systemic corticosteroid treatment with hydrocortisone
10 mg (2e1.5e0) and thyroxine orally was initiated.
MRI of the hypophysitis showed a precise extension of
the posterior pituitary and contrast medium uptake of
the pituitary stalk. After initiation of systemic cortico-
steroids replacement, the general state of the patient
improved.
3.5.2. Patients 12, 13 and 14dDiabetes mellitus type 3
Patient 12: A 70-year-old female patient with no his-
tory of diabetes and normal body mass index (20.6)
sought medical advice after four treatments of first-line
therapy with nivolumab because of increased thirst
and circulatory problems. She was admitted because of
high blood sugar levels and insulin therapy was star-
ted. A new-onset insulin-dependent diabetes type 3
accompanied by a hyperthyreosis was diagnosed. The
glutamic acid decarboxylase (GAD) and the islet
antigen-2 (IA2) antibodies were negative, and c-peptide
was low (<16 pmol/l, normal 140e830 pmol/l). The
cause of the sudden onset of the diabetes was consid-
ered to be an autoimmune reaction triggered by
nivolumab. An MRI scan revealed regression of mel-
anoma and the therapy with nivolumab was continued
to maintain the good tumour response that is still
present as well as the insulin-dependent diabetes.
Patient 13: A 78-year-old female patient with known
diabetes mellitus type 2, which was well controlled
with lifestyle changes (diet, physical activity) and without
the need for medication, was started on treatment
with nivolumab because of progressive metastatic mela-
noma after therapy with ipilimumab. Metformin was
recommended right before initiation of nivolumab. After
two infusions of nivolumab, the patient presented with
vomiting, diarrhoea, and ketoacidosis. She was promptly
admitted and symptomatic treatment as well as an insulinT
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perfusor was started. In the course of the hospitalisation,
the patient developed ketoacidosis again and was trans-
ferred to the intensive care unit. TheGADantibodies were
positive, the c-peptide low, and the IA2 antibodies were
negative. Sudden pancreatic beta cell failure due to an
autoimmune reaction induced by the anti-PD-1 antibodies
was diagnosed. The newly diagnosed type 3 diabetes mel-
litus is currently under control and requires insulin
therapy.
Patient 14: A 58-year-old female patient with no
history of diabetes mellitus had progressive metastatic
melanoma after therapy with ipilimumab. At presenta-
tion for second cycle of pembrolizumab, she complained
about increased thirst and a persistent urge to urinate
that had started the day before. A new- and sudden-
onset insulin-dependent diabetes mellitus type 3 was
diagnosed with low c-peptide, positive GAD II anti-
bodies and IA2 antibodies at the upper limit of normal.
An insulin therapy was initiated and after stabilisation
of the blood glucose levels the second infusion of pem-
brolizumab was administered. The patient continues
with the eighth infusion of pembrolizumab with stable
findings of metastatic disease.
3.6. Renal system
IrAEs affecting the renal system are rare under treat-
ment with anti-CTLA-4 [42] with anecdotic cases of
nephritis [42], acute granulomatous interstitial nephritis
[43], renal failure with atypical pneumonia, vision loss,
and hearing loss [44] and lupus nephritis [45]. Simi-
larly, anti-PD-1 antibodies only rarely induce AEs
affecting the renal system with renal failure/nephritis
reported in up to 1% of pembrolizumab- or
nivolumab-treated patients [5,16,46]. Usually, pause of
treatment and administration of corticosteroids
(0.5e2.0 mg/kg body weight p.o. or i.v.) usually result
in marked improvement [42,47]. In this study, three
cases of renal failure/nephritis were documented in two
patients (0.4%; Table 6). Both patients responded well
to corticosteroid treatment (1.0 mg/kg body weight
p.o. and i.v.) and i.v. substitution of electrolytes.
Because of ongoing elevated creatinine, in one case a
supportive adjuvant application of i.v. fluid before
treatment was necessary.
3.6.1. Patient 15d(Interstitial) Nephritis
A 52-year-old male patient with progressive melanoma
after therapy with ipilimumab received the third infu-
sion of nivolumab. In the laboratory tests, a grade 2
increase in creatinine was detected. The findings in the
urine test were compatible with an interstitial nephritis
and prednisolone 100 mg i.v. was started. In addition,
the patient received i.v. fluids and the potentially
nephrotoxic drugs, i.e. enalapril, indapamide, glime-
piride, and dapagliflozin were stopped. Treatment with
nivolumab was withheld. After a quick improvement to
grade 1 after 3 d, the therapy with corticosteroids was
stopped. After 12 d, the AE was resolved and nivolumab
therapy was restarted. On the day of admission, creati-
nine slightly increased again and, therefore, 500 ml of
0.9% sodium chloride were administered right after the
administration of nivolumab. Additional fluids were
given before all following infusions. Creatinine
increased again and has varied in the course of the
treatment but not higher than grade 1. After discontin-
uation of nivolumab treatment because of progressive
disease and the start of dexamethasone therapy because
of progression of brain metastases with surrounding
oedema, creatinine completely normalised.
4. Discussion
In this study, 496 patient records of 15 skin cancer
centers were screened for anti-PD-1 AEs and 242
interesting, rare or unexpected, side-effects induced by
nivolumab or pembrolizumab were documented in 138
patients (27.8%). Cutaneous, gastrointestinal, hepatic,
endocrine, and renal AEs occurred in 116 of the 138
patients and were summarised: Some events are reported
for the first time like lichen planus and pancreas insuf-
ficiency after pancreatitis. Furthermore, details of rare
side-effects like diabetes mellitus type 3 are reported in 4
patients.
Monitoring of patients for side-effects including
laboratory findings before, during, and after anti-PD-1
therapy is essential. In accordance with the literature
[39], cutaneous AEs under anti-PD-1 treatment are
usually mild and well controlled by symptomatic
therapy. Most commonly, rashes and vitiligo have
been reported. Vitiligo did not require treatment and
was associated with a high disease control rate of 92%
(12 of 13 patients). This is in accordance with the
literature with a disease control rate of 88% (15 in 17
patients) [48]. However, also severe grade 3 lichenoid
skin lesions occurred. Interestingly, Goldinger et al.
[49] observed in 22% of PD-1-treated patients inflam-
matory skin lesions ranging from mild maculopapular
rashes, typically associated with scaling, and/or
lichenoid lesions to very severe StevenseJohnson syn-
drome-like skin lesions. Gene expression profiling
pathogenically classified all investigated cases as toxic
epidermal necrolysis-like reactions. Clinical and histo-
logical features of the lesions resembled the findings
reported in mice with disrupted PD-1 gene [50].
Overall, most reported AEs in this study were
mild with grade 1e2. In this study 24% of AEs
were severe (grade 3e4) and three AEs were fatal due
to pneumonia and ventricular arrhythmia.
In summary, anti-PD-1 antibodies can affect any
organ system and, thus, all symptoms have to be
considered as potentially anti-PD-1 associated. Patients
have to be accurately informed and instructed to report
any symptom. Just as importantly medical staff has to
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Table 5
Endocrine side-effects of anti-PD1 therapy.
Type of side-effect Grade
CTCAE
Anti-PD-1
antibody
Occurrence in
week(s) after
initiation of
anti-PD-1
Treatment of side-effect Outcome of
side-effect
Clinical
tumour
response to
anti-PD-1
Gender
(female/
male)
Age Pre-treatments
Diabetes mellitus type 3 3 n 6 First line: insulin perfusor;
second line: protaphane/actrapid
pen s.c.; pause of nivolumab
Not resolved PD m 40 Dacarbazine; polychemotherapy;
ipilimumab
Hashimoto’s thyroiditis,
hypothyroidism
2 n 5 L-thyroxine 75 mg 1/d Not resolved PR f 53 No prior treatment
Hyperthyroidism 2 n 11 Prednisolone 40 mg p.o. 1/d,
tapering 4 weeks; pause of nivolumab
Hyperthyroidism:
resolved; destructive
thyropathy: not
resolved
PR m 66 No prior treatment
Hyperthyroidism 1 p 3 No treatment Resolved SD f 61 Dacarbazine; ipilimumab;
carboplatin/paclitaxel; fotemustine
Hypothyroidism 2 p 9 L-thyroxine 50 mg 1/d Not resolved SD f 61 Dacarbazine; ipilimumab;
carboplatin/paclitaxel; fotemustine
Hashimoto’s thyroiditis,
hypothyroidism
2 p 18 L-thyroxine 75 mg 1/d Not resolved PR m 46 MEK-inhibitor; dacarbazine;
anti-endosialin-antibody; ipilimumab
Hypocortisolism 2 p 18 Hydrocortisone
15 mg/d p.o.
Not resolved PR m 46 Binimetinib; dacarbazine;
anti-endosialin-antibody; ipilimumab
Pituitary gland: thyreotropic
insufficiency
2 p 10 Dose escalation L-thyroxine
75 mg 1/d
Not resolved PR f 71 Polychemotherapy with litalir;
dacarbazine; carmustine
Hyperthyroidism 2 p 11 Stop of base medication L-thyroxine Resolved PD f 54 Interferon-alpha; vemurafenib/
cobimetinib; ipilimumab;
radiotherapy
Hypothyroidism 1 p 7 No treatment Not resolved PD f 44 Interferon-alpha; dabrafenib;
ipilimumab; vemurafenib;
radiotherapy
Hypophysitis with secondary
adrenal insufficiency
4 p 20 Dexamethasone 4 mg 4/d Resolved PD m 79 No prior treatment
Hypothyroidism (worsening) 1 p 56 L-thyroxine Not resolved CR f 63 Dacarbazine; ipilimumab
Thyroiditis 1 n 12 L-thyroxine Not resolved SD f 54 Dabrafenib; ipilimumab
Thyroiditis 3 p 5 Initial: thiamazole (hyperthyroidism),
following: L-thyroxine
(hypothyroidism)
Not resolved MR m 83 Etoposide
Hypothyroidism 2 p 8 L-thyroxine 50 mg/d Not resolved SD f 65 Ipilimumab; dacarbazine; SIRT;
paclitaxel; radiotherapy
Hypothyroidism 2 p 13 L-thyroxine 50 mg/d Not resolved PR m 78 Dacarbazine; ipilimumab; paclitaxel
Thyroiditis 2 p 3 Thyroid replacement Not resolved PD m 72 Dabrafenib/trametinib; ipilimumab;
carboplatin/paclitaxel
Hyperthyroidism 2 n 7 Carbimazole p.o. Resolved PD f 64 Radiotherapy; SIRT
Hypothyroidism 2 p 6 No treatment Not resolved PR f 48 Ipilimumab
Hyperthyroidism 1 p 15 No treatment Resolved PR m 35 Ipilimumab
Hypothyroidism 1 p 6 No treatment Not resolved PR m 80 Dacarbazine; ipilimumab
Hypothyroidism 2 p 10 L-thyroxine Resolved SD f 63 Dacarbazine; ipilimumab
(continued on next page)
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Table 5 (continued )
Type of side-effect Grade
CTCAE
Anti-PD-1
antibody
Occurrence in
week(s) after
initiation of
anti-PD-1
Treatment of side-effect Outcome of
side-effect
Clinical
tumour
response to
anti-PD-1
Gender
(female/
male)
Age Pre-treatments
Hyperthyroidism with
thyroiditis
1 p 3 No treatment Not resolved PR f 81 Dacarbazine; ipilimumab
Hyperthyroidism 2 p 4 Carbimazole Not resolved SD m 60 Ipilimumab; dacarbazine
Diabetes mellitus type 3 3 n 6 Insulin therapy Not resolved CR f 70 No prior treatment
Diabetes mellitus type 3 3 n 3 Insulin therapy Not resolved SD f 78 Dacarbazine; ipilimumab;
radiotherapy
Pituitary gland: insufficiency
of the anterior lobe
3 n 5 Hydrocortisone p.o. Not resolved PD m 44 Ipilimumab
Hypothyroidism 1 n 2 Methylprednisolone 2 mg/kg/d; stop of
nivolumab
Not resolved PR m 76 Ipilimumab; radiotherapy
Hypophysitis, hypopituitarism 2 n 2 Hydrocortisone p.o. Not resolved PD f 60 Ipilimumab; radiotherapy
Hyperthyroidism 1 n 5 Beta-blocker Not resolved PD f 60 Ipilimumab; radiotherapy
Hypophysitis, hypopituitarism 3 n 5 Pause of nivolumab; prednisolone
initial 50 mg/d
Not resolved SD f 72 Interleukin-2 intratumoural;
imatinib; ipilimumab;
radiotherapy; thermoablatio liver;
electrochemotherapy with bleomycin
Diabetes mellitus type 3 3 p 3 Insulin therapy Not resolved SD f 58 Ipilimumab; radiotherapy
Hypophysitis 2 i/p 17 Systemic hydrocortisone and
thyroxine p.o.
Improved SD m 52 Radiotherapy
Abbreviations: p, pembrolizumab; n, nivolumab; i/p, ipilimumab/pembrolizumab; CTCAE, Common Terminology Criteria for Adverse Events; SD, stable disease, PR, partial response; PD, progressive
disease; CR, complete response; MR, mixed response; SIRT, selective internal radiation therapy; MEK, mitogen-activated protein kinase; p.o., oral; s.c., subcutaneous.
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be informed and remain aware of the side-effect profile
of these immunotherapies. Quite often irAEs start quite
subtle with minimal symptoms. If symptoms are auto-
immune related, prompt treatment including high-dose
corticosteroids can be necessary. Treatment with anti-
PD-1 antibodies only has to be paused when AEs are
severe and can often be resumed as documented in our
study. If AEs are life threatening, anti-PD-1 treatment
has to be discontinued.
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